A
T
P
About
Team
Portfolio
ATP R&D
News
Locations
Contact
Filter by
Year
All
2023
2022
2021
Archive
All
Company
All
ATP
Adendra Therapeutics
Aethon Therapeutics
Ascidian Therapeutics
Aulos Bioscience
Braeburn
Galvanize Therapeutics
Initial Therapeutics
Intergalactic Therapeutics
Marengo Therapeutics
Nereid Therapeutics
Nine Square Therapeutics
Replicate Bioscience
All
May 30, 2023
Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China
May 25, 2023
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells
May 23, 2023
FDA News Release: FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
May 23, 2023
Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
May 16, 2023
Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023
May 11, 2023
Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 09, 2023
Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting
May 01, 2023
With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets
Apr 20, 2023
Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit
Apr 19, 2023
Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023
Apr 18, 2023
Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting
Apr 11, 2023
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic
Mar 22, 2023
Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform
Mar 20, 2023
Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer
Mar 15, 2023
Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies
Mar 14, 2023
Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023
Mar 07, 2023
New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors
Mar 01, 2023
Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer
Mar 01, 2023
Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping and Ablation Catheter
Feb 17, 2023
Gene editing: DNA versus RNA (Drug Discovery News)
Feb 01, 2023
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
Jan 27, 2023
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy
Jan 17, 2023
Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute
Jan 09, 2023
ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells
Jan 06, 2023
Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer
Jan 04, 2023
Ascidian Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 23, 2022
Braeburn Applauds Passage of Significant Advancements in the Treatment of Opioid Use Disorder
Dec 08, 2022
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Nov 10, 2022
Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 10, 2022
Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 10, 2022
Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer
Oct 31, 2022
Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors
Oct 28, 2022
Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022
Oct 17, 2022
New Biotechnology Combines Targeted and Immune Therapies to Kill Treatment-resistant Cancer Cells
Oct 12, 2022
Marengo Therapeutics to Give Plenary Oral Presentation at 34th EORTC-NCI-AACR (ENA) Symposium on Lead Program, STAR0602 and Present Additional Data at the SITC Conference Featuring its Vβ-Targeted Selective T Cell Ac
Oct 12, 2022
Ascidian Therapeutics Launches to Rewrite RNA
Oct 11, 2022
Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 22, 2022
Nereid Therapeutics Co-Founder Clifford Brangwynne Awarded 2023 Breakthrough Prize in Life Sciences
Sep 20, 2022
How 3 companies merged and raised $100M to treat range of diseases by pulsing cells (San Francisco Business Times)
Sep 16, 2022
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
Sep 15, 2022
Galvanize Therapeutics Announces Merger to Create the Premier Pulsed Electric Field Therapy Company and Completion of $100 Million Series B Financing
Sep 13, 2022
Nine Square Therapeutics Appoints John Hood to Board of Directors
Aug 01, 2022
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic
Jul 26, 2022
Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines
Jul 12, 2022
Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors
Jul 12, 2022
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
Jun 15, 2022
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
Jun 09, 2022
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
May 26, 2022
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
May 09, 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
May 05, 2022
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
Apr 27, 2022
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
Mar 21, 2022
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
Mar 09, 2022
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
Mar 07, 2022
Apple Tree Partners Donates to Humanitarian Relief Efforts in Ukraine
Mar 03, 2022
ATP Statement on War in Ukraine
Feb 23, 2022
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Feb 08, 2022
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis
Jan 20, 2022
Intergalactic Therapeutics Announces Scientific Advisory Board Membership
Jan 11, 2022
Nine Square Therapeutics Appoints Robert Paul as CEO
Jan 06, 2022
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
Dec 07, 2021
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Nov 12, 2021
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 08, 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Nov 01, 2021
Nereid Therapeutics Announces Scientific Advisory Board Membership
Oct 25, 2021
Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
Oct 21, 2021
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
Oct 07, 2021
ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding
Oct 05, 2021
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 04, 2021
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Sep 20, 2021
Galaxy Medical Enrolls First Patients in SPACE-AF Study
Sep 08, 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Aug 31, 2021
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Jul 28, 2021
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
Jun 26, 2021
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 15, 2021
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 14, 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
May 20, 2021
Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis
May 17, 2021
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
May 14, 2021
Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile)
May 12, 2021
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
May 08, 2021
Breathing Life into Britain’s Life-Sciences Industry (The Economist)
Mar 30, 2021
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Mar 16, 2021
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Mar 15, 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Mar 02, 2021
Doug Godshall to Chair Gala Therapeutics Board of Directors
Feb 22, 2021
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Jan 08, 2021
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Dec 07, 2020
ATP Forms ATP V With $1 Billion in New Capital Commitments
Nov 16, 2020
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
Oct 08, 2020
First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System
Sep 09, 2020
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Sep 03, 2020
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Aug 12, 2020
Four Questions for Neurology Startups as Venture Investors Pour Millions into the Field (STAT News)
Jul 01, 2020
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Jun 12, 2020
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk
Jun 01, 2020
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
No articles match your selection. Try again.